Japan grants orphan drug status to HAE treatment
CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...
KalVista Announces Orphan Drug Designation And NDA Submission For Sebetralstat In Japan
KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted ...
Le Lézard1d
BCE reports results of Series AE and AF Preferred Share conversions
BCE Inc. today announced that 8,050 of its 8,779,487 fixed-rate Cumulative Redeemable First Preferred Shares, Series AF ("Series AF Preferred Shares") have been tendered for conversion on February 1, ...
KalVista granted orphan drug designation for sebetralstat by MHLW
KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...
PE Hub5d
Medical genetics: 5 PE-backed deals
Archimed, KKR and Novo Holdings are among the PE firms investing in pharma research, development and sales for genetic medicine.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Acquired by Barclays PLC
Barclays PLC increased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 418.5% during the third quarter, Holdings Channel.com reports. The fund owned 67,222 ...
Healio6d
Lanadelumab increases attack-free rates in hereditary angioedema patients
Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study ...